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Abstract
Background: Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large
chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and
assessed potential interactions with conventional therapies.
Methods and Findings: Two independent reviewers searched six databases from inception to March 2009 for evidence
pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for
evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and
two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one
case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears
to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may
reduce risk of lung cancers in populations with lower baseline selenium status (serum,106 ng/mL), but increase risk of lung
cancers in those with higher selenium ($121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung
cancer, OR 0.93 (95% confidence interval 0.61–1.43); other cancers that were the primary endpoints of these trials, OR 1.51
(95%CI 0.70–3.24); and all-cause-death, OR 0.93 (95%CI 0.79–1.10). In the treatment of lung cancers, selenium may reduce
cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.
Conclusions: Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at
present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the
ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is
maintained before any broad clinical recommendations can be made in this context.
Citation: Fritz H, Kennedy D, Fergusson D, Fernandes R, Cooley K, et al. (2011) Selenium and Lung Cancer: A Systematic Review and Meta Analysis. PLoS
ONE 6(11): e26259. doi:10.1371/journal.pone.0026259
Editor: Boris Zhivotovsky, Karolinska Institutet, Sweden
Received May 27, 2011; Accepted September 23, 2011; Published November 4, 2011
Copyright:  2011 Fritz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by a knowledge synthesis grant from the Canadian Institutes of Health Research (CIHR). DAK is supported by a career
training award from the SickKids Foundation. No additional sources of funding were accessed. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dseely@ccnm.edu
Introduction
Lung cancer is a leading cause of cancer death worldwide. The
American Cancer Society projected 159,390 deaths from lung
cancer in 2009, accounting for about 28% of all cancer deaths [1].
Although limiting exposure to cigarette smoke is undoubtedly the
most important prevention strategy, there is a lack of evidence on
chemopreventive strategies for current or former smokers.
Naturally occuring antioxidants such as selenium may hold
promise in this regard. Such therapies are already widely in use:
a recent survey found that over 50% of lung cancer patients
receiving radiation therapy used complementary and alternative
medicines (CAM), with 12% reporting use of selenium specifically
[2].
Selenium is an essential trace element with potent antioxidant
activity mediated through its ability to increase activity of the
glutathione peroxidase enzymes (GPx). Selenium has long been
regarded as possessing anticancer effects based on early experi-
ments from the early 1900s that showed regression of carcinoma
and sarcoma in vivo [3]. Selenium been shown to inhibit DNA
damage in vitro, and reduce pulmonary metastasis and radiation-
induced carcinogenesis in vivo [4,5,6,7]. A meta-analysis of
observational studies has associated selenium levels with decreased
risk of lung cancer [8]. In recent years, selenium has become
controversial following results from the large Selenium and
Vitamin E Cancer Prevention Trial (SELECT), which was
prematurely terminated after demonstrating no effect on prostate
cancer risk [9]. To date, there has been no comprehensive
synthesis of evidence for the use of selenium and lung cancer.
Selenium exists in many forms. The most well studied include
selenomethionine (SeMet), sodium selenite, selenium methylsele-
nocysteine (SeMeSC), 1,4,-phenylenebis (methylene) selenocya-
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composed of selenomethionine predominantly with lesser amounts
of other organic selenium compounds, although concentrations
vary widely according to soil selenium content [10]. Brazil nuts are
known to be a particularly concentrated source of bioavailable
selenium: 2 nuts delivering an average 53 mcg selenium per day
increased plasma selenium levels 64% over 12 weeks, equivalent to
supplementation with 100 mcg selenium as selenomethionine, and
increased GPx 8.3%, superior to selenomethionine (p=0.032)
[11]. ‘‘Selenized’’ or selenium-enriched yeast and selenomethio-
nine are the forms that have been used most frequently in human
trials, with selenized yeast containing 54–62% selenomethionine,
,1% selenite, and small amounts of other selenocompounds
[12,13,14].
Selenium participates in human antioxidant systems as
selenocysteine (SeCys) incorporated into the various selenoproteins
[15]. There are at least 25 selenoproteins known in humans,
including glutathione peroxidase, thioredoxin reductase, iodothyr-
onine deiodinase, and selenoproteins P, W, and R [16,17]. GPx
accounts for 10–30% of plasma selenium, and selenoprotein P
accounts for another 50% [18]. These enzymes protect cells from
free radical damage and regulate DNA transcription and cell
proliferation. The glutathione and thioredoxin systems in
particular have long been considered the major pathways through
which selenium exerts its potential chemopreventive effect [15],
while newer investigations have also suggested growth inhibitory,
proapoptotic activity for selenometabolites in premalignant cells
[19], Finally, selenium is also involved in thyroid function, T cell
immunity, and spermatogenesis [18], and is a competitive
antagonist of potentially carcinogenic heavy metals such as arsenic
and cadmium [20,21].
In order to assess the risks and benefits associated with selenium
supplementation for the treatment and prevention of lung cancer,
we conducted a systematic review of selenium including clinical,
observational, and preclinical evidence. Also included is an
assessment for potential interactions with standard chemo- and
radiation- therapy.
Methods
We searched the following electronic databases for all levels of
evidence pertaining to selenium and lung cancer: Pubmed,
EMBASE, CINAHL, AltHealthWatch, Cochrane, and the Nation-
al Library of Science and Technology. We used a broad based
MeSH and keyword approach combining clinical (lung cancer) and
therapeutic (selenium) search terms: ‘‘(Selenium OR Seleno*) AND
(Lung Neoplasm OR Lung Cancer OR Chemoprevention OR
Chemo*).’’ Two searches were conducted by two independent
investigators (HR and DAK): the first search was conducted in
March 2009 and included all the above databases. Because the first
search identified relatively few studies of interest in the databases
CINAHL, AltHealth Watch, Cochrane and the National Library of
Science and Technology, the second search focused solely on
Pubmed and EMBASE. The second search updated the first search
in August 2009, and was limited to human trials.
Screening of studies was initially conducted based on title
review. In the event of uncertainty, abstracts and/or full texts were
also reviewed. Only English language publications were included.
Human trials had to assess the efficacy of selenium in a population
of predominantly lung cancer patients for the purposes of
treatment, primary or secondary prevention, reduction of side
effects and toxicities associated with chemo- or radiation- therapy,
or assessment of potential interactions with these therapies.
Clinical surrogate studies were included if they examined
endpoints directly related to lung cancer risk, pathogenesis, or
objective markers assessing healthy bodily function such as
hematological function in lung cancer patients. All types of lung
cancers (SCLC, NSCLC, mesothelioma) were included.
To be included, observational studies had to have an objective
measure of selenium status, such as serum, plasma, hair, nail, or
lung tissue selenium levels, and had to examine risk of lung cancer
either prospectively or be conducted in patients with lung cancer
comparing selenium status to patients without cancer. Due to the
high possibility for confounding, studies examining dietary intake
were excluded. Preclinical studies had to be conducted in lung
cancer models and had to examine either anticancer effects of
selenocompounds, or their potential for interaction with conven-
tional chemo- or radiation- therapy. Preclinical studies were
categorized as ‘‘positive,’’ ‘‘negative,’’ ‘‘neutral,’’ or ‘‘mixed.’’ The
term ‘‘positive’’ designates studies that found significant anticancer
effects from at least one of the selenocompounds tested in models
of lung cancer, alone or additively with other agents; ‘‘negative’’
designates studies that found no significant beneficial effect, nor
any evidence of harm. In the absence of reported levels of
significance, the authors’ interpretation was used to guide
classification. Studies examining surrogate markers were included
only if the surrogate related directly to lung cancer risk or
pathogenesis.
We piloted data extraction in duplicate to assess inter-researcher
reliability. Upon completion of data extraction in duplicate for
eighty percent of human level studies, there were no major
inconsistencies, and further duplication of data extraction was
found to be redundant. Both quality and efficacy data were
extracted. Extraction sheets were prepared based on the
Consolidated Standards of Reporting Trials (CONSORT) state-
ment, the Newcastle-Ottawa scale (NOS), and the Score for
Assessment of Physical Experiments on Homeopathy (SAPEH) for
human trials, observational studies, and preclinical studies,
respectively [22,23,24,25]. RCTs were also assessed for quality
using the JADAD scoring system [26].
A third search was conducted in Pubmed and EMBASE from
inception to the end of October 2009 to identify articles pertaining
to selenium and interactions with drugs used in lung cancer
treatment and/or radiation therapy, irrespective of cancer type.
Study types included clinical trials, observational studies, case
reports, and preclinical studies. Data was extracted using piloted
data extraction sheets and analyzed for information pertaining to
pharmacokinetics and interactions.
Statistical Analysis. For randomized controlled trials, outcome
data were pooled using random effects models weighted by the
inverse variance in Comprehensive Meta-analysis Version 2,
Biostat, Englewood, NJ, USA. Results are presented as odds ratios
with 95% confidence intervals. Heterogeneity was assessed using
the I
2 statistic.
Results
Of 3494 records screened, 130 records were included for full
analysis and review. Seventy-eight full text articles and one
conference report were selected for inclusion in the efficacy
analysis. Fifty-one articles were included in the interactions
analysis. Figure 1 shows a flowchart of the literature search and
study selection.
Preclinical Evidence: Mechanism of Action and Forms of
Selenium
Forty-one studies investigating the effect of selenium in
preclinical models of lung cancer were included to better assess
Selenium and Lung Cancer
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with respect to carcinogenesis. Of these, 37 showed results
supporting an anticancer effect for selenium, two showed mixed
results suggesting both pro- and anti- cancer effects, one showed
negative results suggesting detriment from selenium use, and one
showed no significant results in either direction. There were 12
occurrences of studies supporting a anticancer effect for selenium
in vivo; ten studies found effects on cellular redox status,
glutathione peroxidase, and/or thioredoxin activity; seven studies
supported antiproliferative effects or growth inhibition; eight
studies supported proapoptotic effects, six studies supported
cytotoxic effects, four studies supported antimetastatic, anti-
invasive effects; two studies showed an ability to increase survival;
and one study supported an anticancer effect for selenium via
potentiation of immune function. Notably, one study found mixed
effects such that selenium was able to exert anticancer effects in
vivo when animals were exposed to the tobacco nitrosamine NNK,
but not when exposed to cigarette smoke [27]. One study found no
effects on tumor growth but found that selenium decreased body
weight in treated animals to 85% that of the control group [28],
and one study found that selenium both increased glutathione
while suppressing the cytotoxic effect of docosahexanoic acid
(DHA) [29]. The three most commonly used forms of selenium
were pXSC, sodium selenite, and selenomethionine/selenized
yeast. See Table S1.
Surrogate Trials
Trials investigating the effects of selenium supplementation on
surrogate markers of lung cancer risk in at-risk populations and in
lung cancer patients have shown increases in serum and tissue
selenium levels, increases in glutathione, and improved immuno-
logical function. Yu found that selenium enriched rice cakes (300
mcg/d) effectively increased serum and hair selenium 178% and
194.8% respectively, increased serum glutathione peroxidase
(GSH Px) 155.7%, and decreased lipid peroxide levels 74.5%
compared to placebo [30]. Selenium treatment also decreased
unscheduled DNA synthesis (UDS) compared to controls,
indicating less DNA damage and a higher capacity for DNA
repair [30]. Xu found that selenized yeast equivalent to 300 mcg/
d selenium for 14 days significantly increased neutrophil oxidative
Figure 1. Literature Flowchart.
doi:10.1371/journal.pone.0026259.g001
Selenium and Lung Cancer
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26259metabolic activity (as measure of anti-tumor effect) and chemotaxis
in lung cancer patients compared with baseline in the treatment
group but not in the control group [31].
Observational Evidence
Twenty-nine reports of 26 observational studies were included,
three prospective and 23 retrospective or cross-sectional studies.
Two prospective and 14 retrospective or cross-sectional studies
support an inverse association between selenium status and risk of
lung cancer, while one prospective and nine retrospective or cross-
sectional studies showed no significant effect. These studies are
listed in Tables S2 and S3.
Five of the studies listed above found that higher selenium levels
may also be associated with lung cancer, suggesting a possible
biphasic effect for selenium or a U shaped dose-effect curve,
although this evidence is somewhat weak at present. Four studies
suggested a non-significant trend or non-significantly increased
risk with increasing tissue selenium levels [32,33,34,35], and one
study found significantly increased risk of lung cancer in both the
highest and the lowest quartiles of plasma selenium [16]. It is
difficult to determine any clear effect beyond a certain cutoff point
since the studies used different quartile cut-points, and two studies
failed to report cut-points entirely. However, in the two of the
studies there was non-significantly elevated risk of lung cancer in
those with serum selenium between 54 to 121 ng/mL [34], and at
levels .129.3 ng/mL (12.93 mcg/dL) [33]. Jablonska reported
significantly increased risk of lung cancer in both those ,50 ng/
mL (OR 1.90, 95% CI 1.30–2.77) as well as in those with plasma
selenium .90 ng/mL (OR 10.32, 95% CI 1.88–138.2), compared
to those between 50–69 ng/mL [16]. See Table S2.
Controlled Human Trials
Of the five RCTs included, three investigated selenium for
primary prevention of lung cancer, one examined selenium for
secondary prevention in resected early stage lung cancer patients,
and one examined the effect of selenium in conjunction with
cisplatin for the treatment of cancers including lung cancer.
Pooling data from two trials, the Nutritional Prevention of Cancer
(NPC) and the Selenium and Vitamin E Cancer Prevention
(SELECT) trials, showed that selenium had no overall impact on
odds of lung cancer, odds ratio (OR) 0.93 (95% confidence interval
0.61–1.43); odds of the other cancers that were the primary
endpoints of these trials, OR 1.51 (95% CI 0.70–3.24); and odds of
all cause death, OR 0.93 (95% CI 0.79–1.10). Tables S2 and S3
provide a description of study design and outcomes.
Of the RCTs, the Nutritional Prevention of Cancer (NPC) trial
presents the strongest evidence in support of selenium supplemen-
tation to prevent cancer. The NPC study was a multicenter,
randomized, double blind, placebo-controlled trial originally
designed to investigate the effect of 200 mcg selenium as selenium
enriched yeast for 4.5 years on non-melanoma skin cancer
recurrence in 1312 subjects with a history of non-melanoma skin
cancer [36]. The trial failed to show any significant effects on skin
cancer, however, unexpected positive results were found for
incidence of other cancers, including lung cancer. Analysis was
conducted at several time points following: at 6.4 years, total
cancer incidence and mortality were significantly reduced, RR
0.63 (95% CI 0.47–0.85) and RR 0.50 (0.31–0.80), respectively.
Risk of lung cancer was also significantly reduced, RR 0.47 (0.22–
0.98). Overall mortality was non-significantly reduced, RR 0.79
(0.61–1.02) [36,37]. At 7.4 years, the reduction of overall cancer
incidence and mortality remained significant, while there was a
non-significant reduction in lung cancer risk. However, when
analyzed by tertiles of baseline serum selenium, there was a 49%
risk reduction in overall cancer risk in the lowest tertile
(#105.2 ng/mL), a non-significant 30% risk reduction in the
middle tertile, and a non-significant 20% increased risk in the
highest tertile ($121.6 ng/mL). The benefit of selenium in the
lowest tertile only remained significant at 7.9 years, HR 0.42
(0.18–0.96) [38].
Conversely, SELECT found that selenomethionine alone or in
combination vitamin E had no significant effect on the risk of
developing lung cancer in a setting of primary prevention:
selenium, HR 1.12 (95% CI 0.73–1.72); selenium plus vitamin
E, 1.16 (0.76–1.78) [9]. This study was a large, randomized,
double blind, placebo controlled, multicenter study conducted in
35,533 men that investigated selenium, vitamin E, both, or
placebo primarily for the prevention of prostate cancer, but
included rates of lung cancer, other primary cancers, diabetes,
cardiovascular events, and death as secondary outcomes. The
Linxian, China chemoprevention trial also found no effect from a
low dose regimen combining beta carotene, alpha-tocopherol, and
selenium at doses one to two times the US recommended daily
allowance (RDA) for 5.25 years [39]. In findings presented at the
American Society of Clinical Oncology in 2010, Karp reported no
significant effects from use of selenium on lung cancer recurrence
in resected patients, with a second primary tumor rate of 1.91/
4.11 per 100-person years in the selenium group and 1.36/3.66 for
placebo [40]. Five year progression free survival was 72% for
selenium compared to 78% for placebo [40].
Finally, a trial investigating the effect of selenium in conjunction
with cisplatin chemotherapy found that selenium reduced the
toxicity of chemotherapy [41]. Selenium in the form of kappa-
selenocarageenan reduced leukopenia and nephrotoxicity induced
by cisplatin therapy, and reduced the requirement for blood
transfusions (0 vs 62+/238 mL, p,0.05 selenium vs control
group) [41].
Safety and Therapeutic Considerations: Diabetes
Recent findings based on large trials and observational studies
suggest that selenium may increase the risk of diabetes. This was
reported by both the NPC and SELECT trials. The NPC trial
found a 55% increased risk of diabetes among selenium
supplemented subjects, HR 1.55 (95% CI 1.03–2.33) [42], while
the SELECT trial reported a small non-significant increased risk
of diabetes among the selenium group, RR 1.07 (99% CI 0.94–
1.22) [9]. Both studies used selenium predominantly in the form of
selenomethionine, whether in isolation or as selenized yeast, at
doses considerably below the current safe upper limit of 400 mcg/
d [43]. In the NPC trial, an exposure-response gradient was found
across tertiles of baseline plasma selenium level, with risk highest in
the top tertile of baseline plasma selenium level ($121.6 ng/mL,
HR 2.70, 95%CI 1.30–5.61) but non-significant findings in those
below this level [42]. Karp et al failed to show an association
between selenium and diabetes [40].
The NPC trial reported non-significant increased risk for
melanoma, bladder cancer, breast cancer, head and neck cancer,
and lymphoma and leukemia [44]. Other studies have not
corroborated this association [9,40].
Side Effects
Signs and symptoms of selenosis (selenium toxicity) include
pruritis, nail changes, brittle hair and nails, and garlic breath, and
have been reported at serum selenium levels .1000 ng/mL
corresponding to daily intakes .910 mcg [36,45]. At the doses
used therapeutically in intervention trials, mild side effects
generally limited to dermatological and gastrointestinal symptoms
have been reported [36,46]. The SELECT trial also reported
Selenium and Lung Cancer
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and mild to moderate dermatitis (RR 1.17, 1.00–1.35) in the
selenium group, but not the other groups including the one which
had a combination of selenium plus vitamin E [9].
Interactions with Chemotherapy and/or Radiotherapy
Table 1 provides an overview of the effects of various selenium
forms and chemotherapeutic drug combinations in specific cell
lines in vitro [47,48,49,50,51,52,53,54,55]. The effects summarized
include a combination index (CI) between the two substances, if
reported, and when no CI was reported an account of either a
positive or negative impact on neoplastic cell growth from the
combination.
Emphasis is placed here on the pharmacokinetics changes and
adverse events reported in the literature of the various selenium
forms and the chemotherapy drugs used in the treatment of lung
cancer.
In vivo studies
Table S4 summarizes the findings of concurrent chemotherapy
and selenium supplementation in vivo. The most compelling
evidence based on four separate studies is for protection against
nephrotoxicity in cisplatin with selenium administered at least one
hour prior to cisplatin [56,57,58,59]. In two studies, selenium
supplementation allowed for administration of higher doses of
cisplatin, increased survival, and reduced cisplatin resistance
[60,61]; these findings are supported by one RCT that found
reduced nephrotoxicity with concurrent use of selenium and
cisplatin therapy [41].
Clinical studies
Selenium pharmacokinetics in humans as investigated by Fakih
et al are summarized in Table 2 [62,63]. Three studies
investigated selenium supplementation concurrently with chemo-
therapy with varying outcomes including: reduced nephrotoxicity
and leukopenia; improved response to chemotherapy, improved
immune function; and lack of effect on irinotecan pharmacoki-
netics in one study [41,62,64]. Table S5 presents a summary of
these studies. None of the studies reported deleterious interactions
between selenium and chemotherapy.
Radiotherapy
Several studies have found positive outcomes with the use of
sodium selenite, dose range 200–500 mcg/day for up to 10 weeks,
in reducing lymphedema [65,66,67,68,69]. Patients studied
included both arm lymphedema post breast surgery and interstitial
endolaryngeal edema post radiation and surgery in head and neck
tumors. Radiotherapy was found to reduce selenium levels in
gynecological radiation oncology, however, supplementation with
sodium selenite at a dose of 500 mcg/day was found to correct this
deficiency and improve antioxidant status [70,71,72]. In addition,
supplementation with sodium selenite was found to reduce
radiation induced diarrhea and improve survival [73]. A small
study investigating sodium selenite at 5000 mcg/day found
selenium to act as a radioprotecant for healthy cells, and reduce
the incidence of mucositis and xerostomia in head and neck cancer
patients receiving radiation [74].
Discussion
The results of our review suggest that selenium supplementation
may offer benefit among some individuals at risk for cancer,
however its association with increased risk of diabetes warrants
judicious use and further investigation of this substance. The NPC
trial demonstrated that selenium supplementation may reduce risk
of cancer including lung cancer among those with lower serum
selenium (,106 ng/mL) [38], and a second study in lung cancer
patients with low serum selenium (,70.4 ng/mL) found beneficial
effects on leukopenia, hematological toxicity, and nephrotoxicity
associated with cisplatin therapy [41]. The NPC trial reported an
association between with higher selenium levels (.121.6 ng/mL)
and increased risk of diabetes [42], however, and this is
corroborated by observational findings [75]. In the treatment of
cancer, selenium may reduce toxicities and side effects associated
with cisplatin and radiation therapy [41].
Several important questions around selenium supplementation
and cancer prevention require further elucidation. These include
determination of the dose-effect relationship, therapeutic dose,
optimal selenium levels, and the best measure of selenium
adequacy.
Dose-Effect Curve
The results of the NPC trial and sixteen observational studies
suggest that moderate but not very high selenium levels may
reduce risk of lung cancer. In the NPC trial, subjects in the lowest
tertile of serum selenium at baseline (,106 ng/ml) had signifi-
cantly lower risk of lung cancer when given selenium, HR 0.42
(95%CI 0.18–0.96), while those in the highest tertile (.122 ng/
ml) had non-significantly increased risk, HR 1.25 (95%CI 0.49–
3.21) [38]. In addition, there were reports of non-significantly
increased risk with higher selenium status or supplementation in
the NPC trial and four observational studies [32,33,34,35,38], but
only one observational study demonstrated this with statistical
significance [16]. It therefore appears that selenium has its
strongest chemopreventive effects in populations with lower
baseline selenium status, and that above a certain threshold it
may be of limited benefit: this was suggested by a substudy within
the NPC trial: 400mcg was not more effective than placebo in
reducing lung cancer risk even though it elevated serum selenium
levels further than the 200mcg dose, to 250 ng/mL compared to
200 ng/mL by the 200mcg dose [12].
A 2004 meta-analysis of 16 observational also found that
selenium had a protective effect primarily in populations where
average selenium intake is low. Overall, relative risk of lung cancer
for highest versus lowest selenium intake groups was 0.74 (95% CI
0.62–0.88) (p,0.01), with high defined as $100 ng/mL serum
selenium or $55 mcg/d dietary intake [8]. However, this effect
was significant only in areas where population serum levels were
also low, RR 0.72 (0.56–0.93) (p,0.01), and it disappeared in
areas where population selenium levels were higher (.100 mcg/L
or intake .55 mcg/d) RR 0.86 (0.65–1.15) [8].
The divergent effects reported between the NPC and SELECT
trials may also be explained in the context of baseline selenium
status. Authors of the SELECT trial noted: ‘‘the NPC trial was
conducted in men chosen for deficient levels of selenium, and
found that selenium was most preventive in the men with the
lowest baseline selenium levels; SELECT men generally were
replete in selenium at baseline, with median serum selenium levels
of 135 ng/ml vs 113 ng/ml in NPC’’ [9]. It should be noted that
according to the Third National Health and Nutrition Examina-
tion Survey (NHANES III), average plasma selenium concentra-
tions in the United States is 123+/217 ng/mL [76], which places
a large proportion of the US population in the high tertile
according to NPC categorization.
Effect on Diabetes
The NPC trial reported a significantly increased risk of diabetes
associated with selenium supplementation which was more
Selenium and Lung Cancer
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[42]. Recent evidence drawn from large cohort studies such as the
Third National Health and Nutrition Examination Survey
(NHANES III) has corroborated such an association between
higher selenium status and diabetes, adjusted OR 7.64 (95% CI
3.34–17.46) among subjects in the highest quartile of serum
selenium status ($147 mcg/L) compared to those in the lowest
quartile (,124 mcg/L) [75].
Estimates of optimal selenium intake including the Recom-
mended Daily Allowance, currently set at 55 mcg for adults [17],
are based on the dose inducing ‘‘saturation or maximization of
GPx-1 activity’’ [43], however, several scientists have since urged
reevaluation of these recommendations. It has been hypothesized
that selenium may increase GPx (glutathione) activity as a
‘‘compensatory response to oxidative damage’’ [43] induced by
selenium itself rather than as a therapeutic effect. In other words,
selenium in high doses may possess pro-oxidant activity. Induction
of GPx-1 may also be a mechanism through which selenium exerts
its potential diabetogenic effect, since transgenic animal models
overexpressing GPx-1 have been reported to experience hyperin-
sulinemia and insulin resistance [43]. In response to these findings,
it has even been suggested that recommended selenium intakes be
Table 1. Combination effect, in vitro, between forms of Selenium and Chemotherapy drugs.
Chemotherapy CDDP DOC DOX MIC SN38 PAX VP-16
Cell Line
Breast
MCF-7 MseA/q [48,49] ySe/6 [47]
MDA-MB-231 S/6 [50] S/6 [50] S/6 [50] S/6 [50] S/6 [50] S/6 [50]
SK-BR-3 ySe/6 [47]
Colon
SW620 S/q [50]
Caco-2 ySe/6 [47]
HCT116 S/q [50]
Ovarian
2008 ySe/6 [47]
Skov3R MseA/+ [51]
A2780 MseA/Q [52]
Prostate
DU145 MseA/q [53]
S/6 [53]
MseA/q [53,54]
S/6 [53]
MseA/q [53]
S/6 [53]
PC3 MseA/q [53]
S/6 [53]
MseA/q [53,54]
ySe/6 [47]
S/6 [53]
MseA/q [53]
S/6 [53]
Pr14 MseA/q [55]
S/6 [55]
Pr14C1 MseA/q [55]
S/6 [55]
Pr111 MseA/q [55]
S/6 [55]
LnCaP ySe/6 [47]
Liver
HepG2 ySe/6 [47]
Intestinal
HCF8 ySe/6 [47]
Legend
q Additive effect exists where the Combination Index=1. In the article, where the authors calculated the CI and the CI was found to be equal to 1.
+ Positive impact – where the use of the two agents in series or combination resulted in increased growth inhibition that was greater than the single agent alone.
/6 No impact found.
Q Negative impact where the use of the two agents in series or combination resulted in decreased growth inhibition versus the drug agent.
CDDP Cisplatin.
DOC Docetaxel.
DOX Doxorubicin.
MIC Mitomycin C.
MSeA Methylselenic Acid.
PAX Paclitaxel.
S Sodium selenite.
SN38 Active metabolite of irinotecan.
VP-16 Etoposide.
ySe Yeast derived selenium.
doi:10.1371/journal.pone.0026259.t001
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less of inorganic forms [43].
Whether this recommendation can be generalized to patients
receiving chemotherapy is uncertain. The uncertainty comes in
light of the evidence suggesting that higher doses of selenium may
benefit these patients via reductions in toxicity associated with
cisplatin and radiation therapy. It is possible that higher levels of
oxidative stress secondary to chemotherapy increase selenium
requirements in these patients, as with other nutrients. In light of
the current debate around the required amount of selenium in
healthy individuals, however, it seems wise at present to limit long
term, high dose selenium supplementation for the purposes of
chemoprevention unless suboptimal selenium status has been
established.
Measures of Selenium Status
An important question relates to how best to establish
suboptimal selenium status [43,77]. A 2009 systematic review of
methods of selenium status assessment rated all the following
markers as ‘‘useful’’ in assessing changes in selenium status that
occur over a six week or greater period in response to
supplementation: plasma, RBC, and whole-blood selenium,
plasma selenoprotein P, and plasma, platelet, and whole-blood
GPx acitivy [18]. Serum selenium has been the most common
marker used in human supplementation trials, and this is expected
to be similar to plasma values. It has been argued that tissue stores
such as hair and toenail selenium are more reflective of body stores
over a longer period of time compared to serum levels, which are
more liable to change in response to fluctuating dietary patterns,
acute illness, or other stressors. RBC selenium and whole-blood
selenium are reportedly more stable and may act as markers of
longer term status [18].
Forms
The biological activity of selenium in the body depends in part
on its chemical form. Selenium may exist bound as a salt (eg.
sodium selenite); to an amino acid (eg. selenomethionine); or as
methylated forms (eg. methylselenocysteine or Se-methyl-seleno-
cysteine) [78]. Selenomethionine can be converted to selenocys-
teine (SeCys) for use in selenoproteins; alternately, it can be used as
a substitute for methionine in the synthesis of general proteins,
potentially diverting it from its participation in anticancer
pathways [79]. Inorganic salts are metabolized to selenide, which
is then easily incorporated into selenoproteins such as SeCys.
Finally, it has been suggested that methylated forms may be in
large part responsible for selenium’s anticarcinogenic effects
[78,80]. Methylated selenium such as methylselenol (CH3SeH) is
formed in the selenium elimination pathway through methylation
of the potentially more toxic compound dihydrogen selenide
(H2Se) [79]. Alternately, methylselenol can be formed directly
from the methylated selenoamino acids such as Se-methyl-
selenocysteine concentrated by plant sources, such as garlic,
broccoli, and certain Astragalus species, thus avoiding generation
of H2Se [17,43,78,79]. This may be of special relevance for
individuals who have polymorphisms affecting the methylating
abilities of the enzymes required for metabolizing H2Se: Ganther
suggests that these individuals might ‘‘respond poorly to
chemopreventive forms of Se such as inorganic salts or
selenomethionine that are metabolized through the H2Se pool,
but would likely show a response with Se compounds delivering Se
in monomethylated forms’’ [79]. This has also led some to suggest
that while selenomethionine and inorganic forms may be most
effective for increasing selenoprotein activity, sources of methyl-
ated selenium may be most useful for reducing cancer [78].
The preclinical evidence reviewed here includes only a small
amount of data on methylated selenium (methylselenic acid,
methylselenol, Se-methyl-selenocysteine), however studies demon-
strated proapoptotic effects [81,82], antiproliferative effects [82],
promotion of p53-mediated DNA repair [83], and protection
against the carcinogen NNK [84]. The majority of preclinical
studies examined inorganic selenium and the synthetic, organic
selenocompound 1,4-phenylenebis(methylene) selenocyanate (pXSC).
The p-XSC form showed potential in its ability to induce apoptosis
[85,86], inhibit proliferation [85,87], and reduce tumor load in vivo
[7,27,87,88,89,90,91], however it has not yet been tested in humans to
our knowledge.
In human studies the most commonly used forms of selenium
have been selenized yeast (NPC trial) and selenomethionine
(SELECT trial). Selenized yeast contains predominantly seleno-
methionine (54–62%), but also small amounts of selenocysteine, c-
glutamyl-Se-methylselenocysteine, Se-methylselenocysteine, and
several other forms of lower molecular weight [13,14,15].
Following upon the null results of the SELECT trial, it has been
proposed that the more complete spectrum of monomethylated
selenium species contained in selenized yeast or plant sources may
be required for optimal anticancer effects [14].
Validity of Preclinical Lung Cancer Models
Finally, we must consider the validity of preclinical models used
for the investigation of anticancer effects. Chemopreventive effects
of selenium have been shown in several animal models of lung
cancer using NNK or B(a)P as carcinogens. These compounds are
single carcinogens found in cigarette smoke, however they do not
represent the full spectrum of those found in smoke, and it is likley
that the collective effect of hundreds of carcinogens in cigarette
smoke differs from that of single isolated carcinogens. Indeed, in
the three trials using cigarette smoke as the initiating carcinogen,
selenium failed to demonstrate significant protective effects
[27,28,92]. One study directly compared the effect of selenium
on NNK and cigarette smoke induced lung cancer and found
efficacy in the NNK model but not the cigarette model [27].
There is conflicting evidence regarding the potential benefits of
selenium for use in lung cancer chemoprevention. Evidence from
the NPC trial suggests that selenium supplementation may be of
benefit in the prevention of cancer in those with low selenium
status (serum selenium ,106 ng/ml), while supplementation may
increase risk of diabetes among subjects in the higher ranges of
baseline selenium status. Selenium may reduce toxicities associated
with cisplatin chemotherapy and radiation therapy. Further
research is required to clarify optimal dosing strategies and risks
associated with use. An important limitation of this systematic
review is that while comprehensive it only provides an assessment
of efficacy and risk regarding the use of selenium as an individual
agent rather than as part of a combined therapeutic strategy for
Table 2. Selenium pharmacokinetics [62,63].
Form Selenomethionine
Dose 2.2 mg/day
tK 183 hours (7.6 days)
S/E Well tolerated; garlic breath
Max tolerated dose 7.2 mg/day
Blood levels necessary to protect healthy cells 15 mmol/L
doi:10.1371/journal.pone.0026259.t002
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integrative oncology that assesses for the use of selenium and other
natural health products as prescribed and taken in real world
settings is required to better evaluate the additional role selenium
may have for lung cancer prevention and treatment.
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